Молимо вас користите овај идентификатор за цитирање или овај линк до ове ставке:
https://open.uns.ac.rs/handle/123456789/108
Назив: | Adiponectin: a therapeutic target in the antiphospholipid syndrome? | Аутори: | Mirjana Bećarević Božana Nikolić Svetlana Ignjatović |
Кључне речи: | Adiponectin;Antiphospholipid antibodies;Antiphospholipid syndrome;Inflammation;PPAR-gamma agonist | Датум издавања: | 1-сеп-2019 | Часопис: | Rheumatology International | Сажетак: | © 2019, Springer-Verlag GmbH Germany, part of Springer Nature. The antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence of the IgG and/or IgM isotypes of the antiphospholipid antibodies, thrombosis and/or recurrent pregnancy losses. Various markers of inflammation are associated with clinical and/or laboratory features of APS. Adiponectin (Ad) is a member of the adipocytokines that exert its roles by binding to its receptors (AdR). Peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonists induced Ad production. The aged Pparg null-mice represented the first animal model that spontaneously develops APS and this model emphasized the importance of PPAR-gamma signaling in the development of APS. Recombinant Ad (rAd) application was beneficial for the improvement of glucose, insulin and lipid levels in mice. Orally active AdR agonist exerted similar effects to Ad in mice. Due to the re-occurrence of thrombotic episodes in APS patients (despite life-long anticoagulation), administration of PPAR-gamma agonists, rAd, or AdR agonists should be further tested in experimental models of APS, which eventually, will provide more data for novel therapeutic strategies that will ameliorate clinical manifestations of the APS. | URI: | https://open.uns.ac.rs/handle/123456789/108 | ISSN: | 1728172 | DOI: | 10.1007/s00296-019-04349-x |
Налази се у колекцијама: | MDF Publikacije/Publications |
Приказати целокупан запис ставки
SCOPUSTM
Навођења
3
проверено 10.05.2024.
Преглед/и станица
47
Протекла недеља
10
10
Протекли месец
8
8
проверено 10.05.2024.
Google ScholarTM
Проверите
Алт метрика
Ставке на DSpace-у су заштићене ауторским правима, са свим правима задржаним, осим ако није другачије назначено.